查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999310

医疗设备非临床试验服务市场：依服务类型、器材类别、外包模式、动物模型类型、应用和最终用户划分－2026-2032年全球市场预测

Preclinical Medical Device Testing Services Market by Service Type, Device Category, Outsourcing Model, Animal Model Type, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医疗设备非临床试验服务市场价值将达到 38.6 亿美元，到 2026 年将成长至 42.5 亿美元，到 2032 年将达到 76.9 亿美元，复合年增长率为 10.33%。

主要市场统计数据
基准年 2025 38.6亿美元
预计年份：2026年 42.5亿美元
预测年份 2032 76.9亿美元
复合年增长率 (%) 10.33%

为研发团队提供关于临床前医疗设备测试、法规遵循和跨学科操作框架基础知识的全面概述。

临床前医疗设备测试是连接概念性器材设计与首次人体临床试验的关键桥樑，涵盖广泛的科学、工程和监管活动。本导论部分概述了相关人员需要了解的早期开发关键要素。具体而言，这些要素包括检验生物相容性和机械完整性的测试方法、规范证据产生的监管要求，以及管理复杂、多学科专案所需的组织能力。

技术进步、数据驱动的工作流程和自适应测试策略如何重塑临床前医疗设备评估并加速转化可靠性。

在技​​术创新、数据驱动方法和不断变化的监管要求的推动下，临床前医疗设备测试领域正在经历一场变革。影像解析度和即时资料撷取技术的进步使得对医疗设备与组织相互作用的分析更加深入。同时，体外建模和组织工程技术的进步正在减少某些应用中对大型动物试验的依赖。这些变化有助于更早发现失效模式，缩短迭代周期，并支援更可预测的转换路径。

美国近期关税措施对临床前专案供应链多元化和韧性规划的营运和采购影响。

美国近期关税政策的变化为跨境采购设备、生物材料和外包服务的机构带来了新的营运考量。为因应关税政策，供应链调整正日益重视尽可能在国内采购，企业也因此被迫重新评估其试剂和设备供应链的韧性。这些变化对检测计划、供应商选择和成本管理产生了切实的影响，尤其对于那些进行高通量体外检测或依赖专用成像硬体的机构而言更是如此。

将测试调查方法、设备分类、最终用户目标、动物模型选择和应用主导的测试优先顺序连结起来的实用细分见解。

细分为评估临床前试验整体情况的服务需求、技术能力和客户需求提供了一个系统性的观点。从测试技术的角度来看，主要类别包括：生物相容性测试，重点关注细胞毒性、刺激性和致敏性；影像服务，涵盖电脑断层扫描 (CT)、磁振造影(MRI) 和超音波；体外测试，包括细胞分析和组织工程平台；体内测试，区分囓齿类动物模型（小鼠和大鼠）和非囓齿类动物模型，例如犬兔、猪兔、灵长类动物和拉伸；每项技术在基础设施、法规和专业知识方面都有其独特的要求，这些要求决定了服务提供者在哪些方面以及如何投资于自身能力建设。

影响全球创新中心临床前试验供应链、产能投资、监管合作与选址的区域趋势。

区域趋势对服务的实施地点、监管预期的解读以及服务提供者和申办者优先考虑的能力有显着影响。在美洲，强大的临床创新中心和集中的医疗设备製造基地推动了对能够支持快速与监管机构和投资者沟通的全面性临床前服务的需求。在该地区，与临床应用相关的能力，例如大型动物设施、先进的影像设备以及配备严格机械测试设备的实验室，往往备受重视。

供应商之间透过竞争差异化和伙伴关係模式，强调品质体系、一体化服务交付和联合技术投资。

临床前试验服务提供者之间的竞争格局和合作模式呈现出技术深度、服务范围以及整合跨学科专业知识能力​​的差异。大型受託研究机构(CRO) 和专业服务实验室通常透过提供承包服务项目来脱颖而出，这些项目将生物相容性测试、先进成像、体外建模、体内测试和机械检验与强大的计划管理和法规文件支援相结合。小规模的专业服务提供者则倾向于专注于特定领域，例如高解析度成像或客製化组织工程平台，提供深厚的技术专长，以补充大规模全方位服务机构的能力。

为帮助医疗设备开发商和服务供应商降低风险、提高灵活性、加强供应链和加快监管合规准备，提供可操作且优先考虑的建议。

医疗设备研发和服务领域的领导者应采取积极主动的方式来降低技术风险，并加快转化研究的进程。首先，应优先进行早期跨职能规划，整合监管、工程和生物学方面的专业知识，设计一系列试验，以解答关键问题并最大程度地减少重复工作。其次，应投资建构灵活的实体和数位平台，以便在资料累积和假设演进的过程中，轻鬆切换体外、影像和体内实验方法。这将减少代价高昂的返工，并加快决策速度。

我们透过透明、严谨的调查方法确保实际可靠性，该方法结合了相关人员访谈、技术审查、监管资讯整合和交叉检验。

本分析的调查方法结合了多方面的资讯收集和检验手段，旨在确保其准确性、相关性和可操作性。关键的定性资讯是透过与生态系统中各相关人员的结构化访谈收集的，这些利益相关者包括研究所所长、监管专家、产品开发人员和采购经理。这提供了关于营运重点、挑战和不断发展的能力的第一手观点。除了这些对话之外，对标准测试通讯协定和近期同行评审文献的详细技术审查也为观察结果提供了与当前科学实践相符的证据。

整合策略意义和结论性观点，使科学严谨性、营运韧性和区域考量保持一致，以实现转化研究（临床应用）的成功。

这项分析的全面洞见表明，医疗设备的非临床试验处于不断发展的科学、监管审查和运作复杂性的交汇点。影像技术、预测性体外平台和整合资料系统的进步使医疗设备的行为比以往任何时候都更加清晰，而关税和供应链趋势则凸显了建立稳健的采购系统和紧急时应对计画的必要性。細項分析表明，要建立一套强有力的证据包以支持临床开发，需要协调选择测试方法、医疗设备类别、最终用户需求、动物模型和应用目标。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：医疗设备非临床试验服务市场：依服务类型划分

  • 体内试验
    • 生物相容性和毒性测试
    • 植入性能和耐久性
    • 药物动力学和生物分布
    • 安全性和耐受性测试
  • 体外试验
    • 基于细胞的检测
    • 血液相容性测试
    • 遗传毒性和细胞毒性测试
  • 台式试验和机械试验
    • 性能和功能测试
    • 生理和环境压力测试
  • 微生物学和无菌服务
    • 无菌保证和验证
    • 微生物限制测试和微生物附着量测试
    • 抗菌功效测试
  • 包装及保鲜服务
    • 包装完整性测试
    • 运输和配送模拟
    • 加速老化试验和即时老化试验
  • 软体和数位健康试验
    • 内建软体检验
    • 网路安全和连接性测试
    • 人体工学和可用性工程
  • 化学表征服务
    • 萃取和洗脱试验
    • 材料性能评价
    • 残留物和污染物分析

第九章：医疗设备非临床试验服务市场－依医疗设备类别划分

  • 植入式医疗设备
    • 心血管植入
    • 整形外科植入
    • 植入
    • 眼科植入
    • 神经调节植入
  • 非植入式医疗设备
    • 手术器械
    • 创伤护理设备
    • 诊断和监测设备
    • 穿戴式医疗设备
    • 一次性产品
  • 体外诊断医疗设备
    • 试剂组和检测
    • 仪器/分析仪
    • 即时体外诊断（POC）医疗设备

第十章：医疗设备非临床试验服务外包模式市场

  • 全方位外包
  • 职能外包
  • 企划为基础合约
  • 长期策略伙伴关係
  • 内部资源支持

第十一章 依动物模式类型分類的医疗设备非临床试验服务市场

  • 囓齿动物
  • 兔子
  • 狗
  • 猪
  • 非人灵长类动物

第十二章：医疗设备非临床试验服务市场：依应用领域划分

  • 医疗设备安全评价
  • 有效性和性能测试
  • 原型检验
  • 支持向监管机构（FDA/HC）提交申请

第十三章：医疗设备非临床试验服务市场：依最终用户划分

  • 医疗设备製造商
  • 合约研发生产组织（CDMO）
  • 学术和研究机构
    • 大学及教学医院
    • 独立研究机构
  • 政府和非营利组织
    • 公共卫生组织
    • 标准和监管机构
  • 投资者和策略伙伴
    • 创业投资与私募股权
    • 策略企业投资者

第十四章：医疗设备非临床试验服务市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：医疗设备非临床试验服务市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：医疗设备非临床试验服务市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国医疗设备非临床试验服务市场

第十八章：中国医疗设备非临床试验服务市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AGINKO Research AG
  • Bureau Veritas SA
  • Canyon Labs
  • CERTANIA Holding GmbH
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Gradient, Inc.
  • ICON plc
  • Inotiv, Inc.
  • Intertek Group plc
  • IQVIA Holdings Inc.
  • Laboratory Corporation of America Holdings
  • Lahav CRO Ltd.
  • Medistri SA
  • Medpace Holdings, Inc.
  • NAMSA, Inc.
  • Pace Analytical Services, LLC
  • Parexel International（MA）Corporation
  • Pharmaron（Beijing）Co., Ltd.
  • Porsolt SAS
  • RQM+, Inc.
  • SGS SA
  • STEMart
  • Sterigenics International LLC
  • TUV SUD AG
  • UL LLC
  • Veeda Lifesciences
  • Veranex, LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-3A2E844FD678

The Preclinical Medical Device Testing Services Market was valued at USD 3.86 billion in 2025 and is projected to grow to USD 4.25 billion in 2026, with a CAGR of 10.33%, reaching USD 7.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.86 billion
Estimated Year [2026] USD 4.25 billion
Forecast Year [2032] USD 7.69 billion
CAGR (%) 10.33%

Comprehensive foundational overview of preclinical device testing essentials, regulatory alignment, and multidisciplinary operational frameworks for development teams

Preclinical medical device testing forms the critical bridge between conceptual device design and first-in-human studies, encompassing a spectrum of scientific, engineering, and regulatory activities. This introduction distills the essential elements that stakeholders must understand to navigate early development: the testing modalities that validate biological compatibility and mechanical integrity, the regulatory expectations that govern evidence generation, and the organizational capabilities required to manage complex programs across multiple disciplines.

In practice, preclinical testing unites laboratory science with applied engineering. Biocompatibility evaluations must align with standards for cytotoxicity, irritation, and sensitization, while imaging services such as computed tomography, magnetic resonance imaging, and ultrasound provide high-resolution structural and functional readouts. In vitro platforms including cellular assays and tissue engineering systems deliver mechanistic insights, and in vivo studies using rodent and non-rodent models translate those signals into whole-organism contexts. Simultaneously, mechanical testing-spanning compression, tensile, and fatigue assessments-ensures devices survive physiological loads.

This section frames how these components interact to produce robust evidence packages. It emphasizes the importance of early alignment with regulatory pathways, iterative risk management, and integrated data strategies that make preclinical outputs both defensible and translatable. By establishing this baseline, product teams can prioritize experiments, anticipate critical decision points, and design testing cascades that balance scientific rigor with program timelines.

How technological advances, data-driven workflows, and adaptive testing strategies are reshaping preclinical device evaluation and accelerating translational confidence

The landscape of preclinical device testing is undergoing a transformative phase driven by technological innovation, data-centric approaches, and evolving regulatory expectations. Advances in imaging resolution and real-time data acquisition are enabling more nuanced characterization of device-tissue interactions, while improvements in in vitro modeling and tissue engineering are reducing reliance on large animal studies for certain applications. These shifts are encouraging earlier detection of failure modes, shortening iteration cycles, and supporting more predictive translational pathways.

Concurrently, the integration of digital tools, from sophisticated image analysis algorithms to laboratory information management systems, is streamlining data curation and accelerating cross-disciplinary collaboration. This is complemented by growing emphasis on reproducibility and standardized protocols, which improve comparability across studies and increase confidence in results submitted to regulators. In parallel, there is a discernible shift toward modular testing strategies that combine targeted in vitro assays, focused imaging endpoints, and bespoke in vivo protocols to deliver efficient yet comprehensive evidence of safety and performance.

Taken together, these developments are reshaping vendor-sponsor relationships and the design of preclinical programs. Labs that invest in flexible platforms, scalable data infrastructures, and cross-trained teams are positioned to deliver higher-value services. Product developers who adopt adaptive testing cascades and prioritize early engagement with multidisciplinary experts will be better placed to manage technical risk and reduce downstream surprises during clinical translation.

Operational and procurement consequences of recent United States tariff measures that are prompting supply chain diversification and resilience planning in preclinical programs

Recent tariff dynamics within the United States have introduced new operational considerations for organizations that procure equipment, biological materials, and outsourced services across borders. Supply chain adjustments in response to tariff policies have raised the premium on domestic sourcing where feasible, and have also prompted firms to reassess the resilience of reagent and instrumentation pipelines. These shifts have tangible implications for test planning, vendor selection, and cost management, particularly for entities conducting high-throughput in vitro assays or relying on specialized imaging hardware.

As a consequence, sponsors and service providers are increasingly evaluating alternative sourcing strategies and regional manufacturing partnerships to mitigate exposure to tariff-driven disruptions. This has led to a rise in forward-looking procurement practices such as dual-sourcing critical consumables, negotiating supply contracts with clarity on tariff pass-through, and validating alternate equipment suppliers where technical equivalence can be demonstrated. Additionally, organizations are paying closer attention to lead times for animal models and importing biological reagents, recognizing that even small delays can cascade into program timeline risks.

Strategically, the tariff environment is reinforcing the importance of supply chain transparency and proactive risk assessment during preclinical planning. Teams that incorporate contingency plans, maintain validated alternative protocols, and invest in vendor qualification processes can reduce operational volatility. Moreover, manufacturers of testing equipment and consumables that offer localized service and support find themselves increasingly attractive to sponsors seeking predictable delivery and minimal regulatory risk associated with component substitutions.

Actionable segmentation insights connecting testing methodologies, device classes, end-user objectives, animal model selection, and application-driven testing priorities

Segmentation provides a structured lens to evaluate service demand, technical capabilities, and client needs across the preclinical testing landscape. When examined through the prism of testing technique, key categories include biocompatibility testing with focused assays for cytotoxicity, irritation, and sensitization; imaging services that span computed tomography, magnetic resonance imaging, and ultrasound; in vitro testing comprising cellular assays and tissue engineering platforms; in vivo testing that differentiates rodent models (mice and rats) and non-rodent models with species such as dogs, pigs, primates, and rabbits; and mechanical testing encompassing compression, fatigue, and tensile evaluations. Each technique has distinct infrastructure, regulatory, and expertise requirements, shaping where and how providers invest in capabilities.

Considering device category, demand profiles diverge across cardiovascular devices including heart valves and stents, dental solutions such as implants and orthodontic devices, neurological products like monitoring devices and neurostimulators, ophthalmic technologies including intraocular lenses and laser systems, and orthopedic offerings comprising implants and prosthetics. Device class influences the prioritization of certain assays and models: cardiovascular and orthopedic devices often require rigorous mechanical testing and relevant large or non-rodent models, whereas ophthalmic and neurological devices may place greater weight on sophisticated imaging and targeted biocompatibility endpoints.

From an end-user perspective, academic institutes, contract research organizations-with full service and niche providers-hospitals including research and teaching centers, medical device manufacturers that range from large OEMs to smaller firms, and pharmaceutical or biotech companies each approach preclinical testing with different objectives and timelines. Academic groups typically pursue exploratory hypothesis-driven work, CROs deliver regulated, scalable studies, hospitals may focus on translational feasibility, manufacturers prioritize product validation and regulatory readiness, and pharma/biotech entities often seek integrated safety and compatibility assessments.

Examining animal model type reveals a layered decision framework: large animal models such as pigs and primates are selected for anatomical or physiological congruence, non-rodent models including dogs and rabbits serve intermediate translational needs, and rodent models-mice and rats-are used for early mechanistic and safety profiling. Finally, application-based segmentation distinguishes functional testing for electrical and mechanical functionality from performance testing that evaluates fatigue and wear, and safety testing that comprises cytotoxicity, hemocompatibility, and systemic toxicity assessments. Integrating these segmentation dimensions enables sponsors to design cohesive testing cascades that align scientific questions with the most appropriate methods and models.

Regional dynamics shaping preclinical testing supply chains, capability investments, regulatory interactions, and site selection across global innovation hubs

Regional dynamics strongly influence where services are performed, how regulatory expectations are interpreted, and what capabilities are prioritized by providers and sponsors. In the Americas, robust clinical innovation hubs and a concentrated base of device manufacturers drive demand for integrated preclinical services that can support rapid regulatory interactions and investor engagement. This region often emphasizes capabilities tied to clinical translation, including large-animal facilities, advanced imaging suites, and laboratories equipped for rigorous mechanical testing.

In Europe, Middle East & Africa, the landscape is more fragmented with a spectrum of regulatory frameworks and academic excellence centers that foster specialized capabilities. Providers here frequently focus on harmonizing protocols to meet diverse regulatory requirements and often leverage collaborative networks to access niche expertise. The need for interoperability of data and adherence to pan-regional standards encourages investments in documentation practices and protocol harmonization, enabling sponsors to pursue multi-jurisdictional strategies.

Across Asia-Pacific, rapid manufacturing growth and expanding biomedical research ecosystems are creating significant demand for scalable testing services and cost-competitive operations. Laboratories in this region are increasingly adopting advanced imaging and in vitro platforms while scaling animal model facilities to support both local and international sponsors. Additionally, the Asia-Pacific region is notable for accelerating adoption of novel testing approaches, supported by investments in automation and digital infrastructure that streamline throughput and support cross-border collaborations.

Understanding these regional textures is essential for aligning vendor partnerships with program objectives, whether that means prioritizing rapid clinical translation in the Americas, seeking harmonized regulatory approaches in Europe, Middle East & Africa, or leveraging scalable, cost-efficient capabilities in Asia-Pacific. Each regional context brings distinct operational considerations that should inform site selection, data package composition, and timelines.

Competitive differentiation and partnership models among providers emphasizing quality systems, integrated service delivery, and collaborative technology investments

The competitive and collaborative landscape among providers of preclinical testing services is characterized by differentiation in technical depth, breadth of service offerings, and the ability to integrate cross-disciplinary expertise. Leading contract research organizations and specialized service labs often distinguish themselves by offering turnkey programs that combine biocompatibility testing, advanced imaging, in vitro modeling, in vivo study execution, and mechanical validation with strong project management and regulatory documentation support. Smaller niche providers frequently focus on specific modalities, such as high-resolution imaging or bespoke tissue engineering platforms, offering deep technical expertise that complements larger full-service capabilities.

Strategically, successful companies invest heavily in quality systems, traceability, and documentation to meet stringent regulatory requirements. They also cultivate scientific partnerships with academic centers and device manufacturers to co-develop novel assays, optimize models, and validate new imaging biomarkers. Operational agility-manifested through modular service offerings, rapid protocol adaptation, and integrated data delivery-is another distinguishing factor that clients increasingly prioritize. Moreover, organizations that provide transparent data integration tools and clear pathways for regulatory submission support earn higher trust from sponsors navigating complex approval pathways.

Ultimately, the most resilient providers blend technical excellence with service flexibility. Whether through geographic expansion, targeted technology investments, or collaborative service models, companies that align their capabilities with sponsor needs for speed, reproducibility, and regulatory defensibility position themselves as preferred partners for advancing device innovation.

Practical and prioritized recommendations for device developers and service providers to reduce risk, increase agility, strengthen supply chains, and accelerate regulatory readiness

Leaders in device development and service provision should adopt a proactive stance to reduce technical risk and accelerate translational timelines. First, prioritize early, cross-functional planning that brings regulatory, engineering, and biological expertise together to design testing cascades that answer pivotal questions with minimal redundancy. Second, invest in flexible platforms-both physical and digital-that enable switching between in vitro, imaging, and in vivo modalities as data accumulates and hypotheses evolve. This reduces costly rework and improves decision velocity.

Third, strengthen supply chain resilience by qualifying multiple sources for critical consumables and equipment, and by maintaining validated alternative protocols that can be deployed with minimal disruption. Fourth, cultivate strategic partnerships with providers that demonstrate both deep technical competence in specific modalities and the ability to integrate into broader evidence generation programs. Fifth, institutionalize robust data management practices that ensure traceability, reproducibility, and ease of regulatory submission; this includes adopting standardized reporting templates and investing in analytics tools that synthesize cross-modal outputs.

Finally, prioritize workforce development by cross-training scientists and technicians across assay types and data systems, and by fostering a culture of continuous improvement. Together, these actions will reduce program risk, accelerate timelines to clinical readiness, and enhance the credibility of preclinical packages submitted to regulatory authorities.

Transparent and rigorous research methodology combining stakeholder interviews, technical review, regulatory synthesis, and cross-validation to ensure actionable reliability

The research methodology underpinning this analysis combines a multi-pronged information gathering and validation approach designed to ensure accuracy, relevance, and actionable insight. Primary qualitative inputs were sourced through structured interviews with stakeholders across the ecosystem, including laboratory directors, regulatory specialists, product developers, and procurement leads, enabling firsthand perspectives on operational priorities, pain points, and evolving capabilities. These dialogues were complemented by in-depth technical reviews of standard testing protocols and recent peer-reviewed literature to ground observations in current scientific practice.

Secondary sources comprised authoritative regulatory guidance documents, consensus standards, and white papers that clarify evidentiary expectations for device safety and performance. Comparative analysis across service provider capabilities and regional infrastructure was conducted to identify operational patterns and capability gaps. Throughout, triangulation methods were applied: findings from interviews were cross-referenced with documented practices and technical literature to validate trends and contextualize strategic implications.

Analytical rigor was maintained by focusing on reproducibility and transparency. Assumptions and inclusion criteria for service categories, device classes, end users, animal models, and application domains were explicitly defined to ensure clarity. Wherever applicable, methodological limitations and areas of uncertainty are highlighted so that readers can interpret insights with appropriate context and confidence.

Synthesis of strategic implications and concluding perspectives that align scientific rigor, operational resilience, and regional considerations for translational success

The cumulative narrative of this analysis underscores that preclinical medical device testing sits at the intersection of evolving science, regulatory scrutiny, and operational complexity. Advances in imaging, predictive in vitro platforms, and integrated data systems are providing unprecedented clarity into device behavior, while tariff and supply chain dynamics underscore the need for resilient procurement and contingency planning. Segmentation analysis reveals that the choice of testing technique, device category, end-user needs, animal model, and application purpose must be harmonized to produce robust evidence packages that support clinical progression.

Providers and sponsors that align capabilities with regulatory expectations, invest in quality systems and data integration, and adopt flexible testing cascades will be best positioned to reduce translational risk. Regional considerations further inform where to locate critical studies and how to structure cross-border programs, with each geography offering distinct strengths in clinical translation, harmonization, or scalable capacity. Ultimately, the path to efficient and credible preclinical programs lies in early multidisciplinary planning, rigorous methodological execution, and continuous adaptation to technological and operational shifts.

This conclusion emphasizes practical foresight: by integrating scientific rigor with strategic supply chain management and by choosing partners that can deliver reproducible, well-documented results, organizations can enhance the probability of successful clinical translation and long-term product adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preclinical Medical Device Testing Services Market, by Service Type

  • 8.1. In Vivo Testing
    • 8.1.1. Biocompatibility & Toxicology Studies
    • 8.1.2. Implant Performance & Durability
    • 8.1.3. Pharmacokinetics & Biodistribution
    • 8.1.4. Safety & Tolerability Studies
  • 8.2. In Vitro Testing
    • 8.2.1. Cell-Based Assays
    • 8.2.2. Hemocompatibility Testing
    • 8.2.3. Genotoxicity & Cytotoxicity Testing
  • 8.3. Bench & Mechanical Testing
    • 8.3.1. Performance & Functional Testing
    • 8.3.2. Physical & Environmental Stress Testing
  • 8.4. Microbiology & Sterility Services
    • 8.4.1. Sterility Assurance & Validation
    • 8.4.2. Microbial Limits & Bioburden Testing
    • 8.4.3. Antimicrobial Efficacy Testing
  • 8.5. Packaging & Shelf-Life Services
    • 8.5.1. Package Integrity Testing
    • 8.5.2. Transportation & Distribution Simulation
    • 8.5.3. Accelerated & Real-Time Aging Studies
  • 8.6. Software & Digital Health Testing
    • 8.6.1. Embedded Software Verification
    • 8.6.2. Cybersecurity & Connectivity Testing
    • 8.6.3. Human Factors & Usability Engineering
  • 8.7. Chemical Characterization Services
    • 8.7.1. Extractables & Leachables Studies
    • 8.7.2. Material Characterization
    • 8.7.3. Residuals & Contaminants Analysis

9. Preclinical Medical Device Testing Services Market, by Device Category

  • 9.1. Implantable Devices
    • 9.1.1. Cardiovascular Implants
    • 9.1.2. Orthopedic Implants
    • 9.1.3. Dental Implants
    • 9.1.4. Ophthalmic Implants
    • 9.1.5. Neuromodulation Implants
  • 9.2. Non Implantable Devices
    • 9.2.1. Surgical Instruments
    • 9.2.2. Wound Care Devices
    • 9.2.3. Diagnostic & Monitoring Equipment
    • 9.2.4. Wearable Medical Devices
    • 9.2.5. Single Use Disposables
  • 9.3. In Vitro Diagnostic Devices
    • 9.3.1. Reagent Kits & Assays
    • 9.3.2. Instruments & Analyzers
    • 9.3.3. Point Of Care IVD Devices

10. Preclinical Medical Device Testing Services Market, by Outsourcing Model

  • 10.1. Full-Service Outsourcing
  • 10.2. Functional Outsourcing
  • 10.3. Project-Based Engagements
  • 10.4. Long-Term Strategic Partnerships
  • 10.5. Insourcing Support

11. Preclinical Medical Device Testing Services Market, by Animal Model Type

  • 11.1. Rodents
  • 11.2. Rabbits
  • 11.3. Canines
  • 11.4. Swine
  • 11.5. Non-Human Primates

12. Preclinical Medical Device Testing Services Market, by Application

  • 12.1. Device Safety Assessment
  • 12.2. Efficacy & Performance Studies
  • 12.3. Prototype Validation
  • 12.4. Regulatory Submission Support (FDA/HC)

13. Preclinical Medical Device Testing Services Market, by End-User

  • 13.1. Medical Device Manufacturers
  • 13.2. Contract Development & Manufacturing Organizations
  • 13.3. Academic & Research Institutions
    • 13.3.1. Universities & Teaching Hospitals
    • 13.3.2. Independent Research Institutes
  • 13.4. Government & Nonprofit Organizations
    • 13.4.1. Public Health Agencies
    • 13.4.2. Standards & Regulatory Bodies
  • 13.5. Investors & Strategic Partners
    • 13.5.1. Venture Capital & Private Equity
    • 13.5.2. Strategic Corporate Investors

14. Preclinical Medical Device Testing Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Preclinical Medical Device Testing Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Preclinical Medical Device Testing Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Preclinical Medical Device Testing Services Market

18. China Preclinical Medical Device Testing Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AGINKO Research AG
  • 19.6. Bureau Veritas S.A.
  • 19.7. Canyon Labs
  • 19.8. CERTANIA Holding GmbH
  • 19.9. Charles River Laboratories International, Inc.
  • 19.10. Eurofins Scientific SE
  • 19.11. Gradient, Inc.
  • 19.12. ICON plc
  • 19.13. Inotiv, Inc.
  • 19.14. Intertek Group plc
  • 19.15. IQVIA Holdings Inc.
  • 19.16. Laboratory Corporation of America Holdings
  • 19.17. Lahav CRO Ltd.
  • 19.18. Medistri SA
  • 19.19. Medpace Holdings, Inc.
  • 19.20. NAMSA, Inc.
  • 19.21. Pace Analytical Services, LLC
  • 19.22. Parexel International (MA) Corporation
  • 19.23. Pharmaron (Beijing) Co., Ltd.
  • 19.24. Porsolt SAS
  • 19.25. RQM+, Inc.
  • 19.26. SGS SA
  • 19.27. STEMart
  • 19.28. Sterigenics International LLC
  • 19.29. TUV SUD AG
  • 19.30. UL LLC
  • 19.31. Veeda Lifesciences
  • 19.32. Veranex, LLC
  • 19.33. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BIOCOMPATIBILITY & TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BIOCOMPATIBILITY & TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BIOCOMPATIBILITY & TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANT PERFORMANCE & DURABILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANT PERFORMANCE & DURABILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANT PERFORMANCE & DURABILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHARMACOKINETICS & BIODISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHARMACOKINETICS & BIODISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHARMACOKINETICS & BIODISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SAFETY & TOLERABILITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SAFETY & TOLERABILITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SAFETY & TOLERABILITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CELL-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CELL-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HEMOCOMPATIBILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HEMOCOMPATIBILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HEMOCOMPATIBILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GENOTOXICITY & CYTOTOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GENOTOXICITY & CYTOTOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GENOTOXICITY & CYTOTOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PERFORMANCE & FUNCTIONAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PERFORMANCE & FUNCTIONAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PERFORMANCE & FUNCTIONAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHYSICAL & ENVIRONMENTAL STRESS TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHYSICAL & ENVIRONMENTAL STRESS TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PHYSICAL & ENVIRONMENTAL STRESS TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STERILITY ASSURANCE & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STERILITY ASSURANCE & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STERILITY ASSURANCE & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIAL LIMITS & BIOBURDEN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIAL LIMITS & BIOBURDEN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIAL LIMITS & BIOBURDEN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANTIMICROBIAL EFFICACY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANTIMICROBIAL EFFICACY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANTIMICROBIAL EFFICACY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGE INTEGRITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGE INTEGRITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGE INTEGRITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY TRANSPORTATION & DISTRIBUTION SIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY TRANSPORTATION & DISTRIBUTION SIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY TRANSPORTATION & DISTRIBUTION SIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACCELERATED & REAL-TIME AGING STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACCELERATED & REAL-TIME AGING STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACCELERATED & REAL-TIME AGING STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SOFTWARE & DIGITAL HEALTH TESTING, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EMBEDDED SOFTWARE VERIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EMBEDDED SOFTWARE VERIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EMBEDDED SOFTWARE VERIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CYBERSECURITY & CONNECTIVITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CYBERSECURITY & CONNECTIVITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CYBERSECURITY & CONNECTIVITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HUMAN FACTORS & USABILITY ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HUMAN FACTORS & USABILITY ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY HUMAN FACTORS & USABILITY ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CHEMICAL CHARACTERIZATION SERVICES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EXTRACTABLES & LEACHABLES STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EXTRACTABLES & LEACHABLES STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EXTRACTABLES & LEACHABLES STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MATERIAL CHARACTERIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MATERIAL CHARACTERIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MATERIAL CHARACTERIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RESIDUALS & CONTAMINANTS ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RESIDUALS & CONTAMINANTS ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RESIDUALS & CONTAMINANTS ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DENTAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DENTAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DENTAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OPHTHALMIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OPHTHALMIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OPHTHALMIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NEUROMODULATION IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NEUROMODULATION IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NEUROMODULATION IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON IMPLANTABLE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WOUND CARE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WOUND CARE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WOUND CARE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC & MONITORING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WEARABLE MEDICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WEARABLE MEDICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY WEARABLE MEDICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SINGLE USE DISPOSABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SINGLE USE DISPOSABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SINGLE USE DISPOSABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REAGENT KITS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REAGENT KITS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REAGENT KITS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY POINT OF CARE IVD DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY POINT OF CARE IVD DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY POINT OF CARE IVD DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY OUTSOURCING MODEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FUNCTIONAL OUTSOURCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FUNCTIONAL OUTSOURCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY FUNCTIONAL OUTSOURCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROJECT-BASED ENGAGEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROJECT-BASED ENGAGEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROJECT-BASED ENGAGEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY LONG-TERM STRATEGIC PARTNERSHIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY LONG-TERM STRATEGIC PARTNERSHIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY LONG-TERM STRATEGIC PARTNERSHIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSOURCING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSOURCING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INSOURCING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ANIMAL MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RABBITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RABBITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CANINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CANINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CANINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON-HUMAN PRIMATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON-HUMAN PRIMATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY NON-HUMAN PRIMATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY DEVICE SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EFFICACY & PERFORMANCE STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EFFICACY & PERFORMANCE STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY EFFICACY & PERFORMANCE STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROTOTYPE VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROTOTYPE VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PROTOTYPE VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGULATORY SUBMISSION SUPPORT (FDA/HC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGULATORY SUBMISSION SUPPORT (FDA/HC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGULATORY SUBMISSION SUPPORT (FDA/HC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY UNIVERSITIES & TEACHING HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY UNIVERSITIES & TEACHING HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY UNIVERSITIES & TEACHING HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INDEPENDENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INDEPENDENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INDEPENDENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY GOVERNMENT & NONPROFIT ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STANDARDS & REGULATORY BODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STANDARDS & REGULATORY BODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STANDARDS & REGULATORY BODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY INVESTORS & STRATEGIC PARTNERS, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY VENTURE CAPITAL & PRIVATE EQUITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY VENTURE CAPITAL & PRIVATE EQUITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY VENTURE CAPITAL & PRIVATE EQUITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STRATEGIC CORPORATE INVESTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STRATEGIC CORPORATE INVESTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY STRATEGIC CORPORATE INVESTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VIVO TESTING, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY IN VITRO TESTING, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY BENCH & MECHANICAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY & STERILITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS PRECLINICAL MEDICAL DEVICE TESTING SERVICES MARKET SIZE, BY PACKAGING & SHELF-LIFE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS PRECLI